日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Dynamics of complete responses (CRs) in patients with relapsed or refractory follicular lymphoma (R/R FL) treated with odronextamab in the ELM-2 study

ELM-2 研究中接受 odronextamab 治疗的复发或难治性滤泡性淋巴瘤 (R/R FL) 患者的完全缓解 (CR) 动态变化

期刊:Hemasphere
影响因子:14.6
doi:10.1002/hem3.70300
Luminari, Stefano; Jiménez-Ubieto, Ana; Chong, Geoffrey; Tucker, David; Ambati, Srikanth; Lin, Chinjune; Mohamed, Hesham; Brouwer-Visser, Jurriaan; Otele, Chetachi Akunna; Antico, Giovanni; Villasboas, Jose C
淋巴瘤
发表日期：2026
文献求助 收藏

Fluticasone- vs Budesonide-Based Dual Therapy for COPD

氟替卡松与布地奈德联合疗法治疗慢性阻塞性肺疾病

期刊:Jama Network Open
影响因子:9.7
doi:10.1001/jamanetworkopen.2026.0959
Feldman, William B; Ambati, Vidya L; Suissa, Samy; Kesselheim, Aaron S; Avorn, Jerry; Schneeweiss, Sebastian; Wang, Shirley V
慢性阻塞性肺疾病
发表日期：2026
文献求助 收藏

Stem cells in organogenesis and regeneration

干细胞在器官发生和再生中的作用

期刊:Stem Cell Research & Therapy
影响因子:7.3
doi:10.1186/s13287-025-04889-z
Mim, Tasmia Jahin; Ahmad, Iftakhar; Basher, Salima Raiyan; Rahman, Md Foyzur; Ambati, Sandeep Reddy; Venkatagiri, Kiranmai; Seher, Nimrah; Kumar, Dinesh; Choudhary, Neeraj; Kondaveeti, Suresh Babu
细胞生物学
发育与干细胞
干细胞
发表日期：2026
文献求助 收藏

Leveraging untargeted metabolomics in combination with machine learning to uncover novel insights into bladder cancer

利用非靶向代谢组学结合机器学习技术，揭示膀胱癌的新见解

期刊:Cancer & Metabolism
影响因子:5.3
doi:10.1186/s40170-026-00427-4
Kamal, Abu Hena Mostafa; Putluri, Vasanta; Gandhi, Tanmay; Ambati, Chandra Shekar R; Amara, Chandra Sekhar; Kami Reddy, Karthik Reddy; Spradlin, Meredith Lauren; Koirala, Amrit; Jorvekar, Sachin B; Grimm, Sandra L; Fu, Dexue; Parsawar, Krishna; Jong, Felice de; Beecher, Chris; Sen, Subrata; Lerner, Seth P; Siddiqui, M Minhaj; Lotan, Yair; Eberlin, Livia S; Sreekumar, Arun; Coarfa, Cristian; Putluri, Nagireddy
肿瘤
肿瘤免疫
膀胱癌
代谢
发表日期：2026
文献求助 收藏

An adaptive acceleration scheme for phase-field fatigue computations

一种用于相场疲劳计算的自适应加速方案

期刊:Computational Mechanics
影响因子:3.8
doi:10.1007/s00466-024-02551-8
Heinzmann, Jonas; Carrara, Pietro; Ambati, Marreddy; Mirzaei, Amir Mohammad; De Lorenzis, Laura
发表日期：2026
文献求助 收藏

Acute cardiovascular events after discontinuation of xanthine oxidase inhibitors: a cohort study

停用黄嘌呤氧化酶抑制剂后发生急性心血管事件：一项队列研究

期刊:Clinical Rheumatology
影响因子:2.8
doi:10.1007/s10067-025-07899-7
Magagnoli, Joseph; Cummings, Tammy H; Ambati, Meenakshi; Sutton, S Scott; Ambati, Jayakrishna
发表日期：2026
文献求助 收藏

Glycated CD59: an emerging biomarker of diabetic nephropathy associated with microalbuminuria, tubular damage, and complement activation.

糖化 CD59：一种与微量白蛋白尿、肾小管损伤和补体激活相关的糖尿病肾病的新兴生物标志物。

期刊:Journal of Diabetes and Metabolic Disorders
影响因子:1.6
doi:10.1007/s40200-025-01849-5
Chinta Bhagatsingh, Padma Sunethri, Ambati Ranga Rao
糖尿病
糖尿病肾病
代谢
CD5
CD59
发表日期：2026
文献求助 收藏

Efficacy of Curcumin Gel Versus Hyaluronic Acid as Adjuvants to Scaling and Root Planing on IL-1β Levels in Smokers With Chronic Periodontitis

姜黄素凝胶与透明质酸作为辅助剂治疗慢性牙周炎吸烟者牙周刮治术对IL-1β水平的影响

期刊:Cureus Journal of Medical Science
影响因子:1.3
doi:10.7759/cureus.101405
Devarampati, Laxmi Jaahnavi; Koduganti, Rekha R; Panthula, Veerendranath Reddy; Surya Prasanna, Jammula; Gireddy, Hima Bindu; Ambati, Manasa
IL-1β
发表日期：2026
文献求助 收藏

Author Correction: Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial

作者更正：Odronextamab 单药治疗复发/难治性弥漫性大 B 细胞淋巴瘤患者：ELM-2 II 期试验的主要疗效和安全性分析

期刊:Nature Cancer
影响因子:28.5
doi:10.1038/s43018-025-00967-6
Kim, Won Seog; Kim, Tae Min; Cho, Seok-Goo; Jarque, Isidro; Iskierka-Jażdżewska, Elżbieta; Poon, Li Mei; Prince, H Miles; Zhang, Huilai; Cao, Junning; Zhang, Mingzhi; Tessoulin, Benoît; Oh, Sung Yong; Lim, Francesca; Carpio, Cecilia; Tan, Tran-Der; Ayyappan, Sabarish; Gutierrez, Antonio; Cai, Jingxian; Ufkin, Melanie; Shariff, Saleem; Brouwer-Visser, Jurriaan; Chaudhry, Aafia; Mohamed, Hesham; Ambati, Srikanth; Walewski, Jan
细胞生物学
淋巴瘤
T细胞
发表日期：2025
文献求助 收藏

Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial

Odronextamab单药治疗复发/难治性弥漫性大B细胞淋巴瘤患者：ELM-2 II期试验的主要疗效和安全性分析

期刊:Nature Cancer
影响因子:28.5
doi:10.1038/s43018-025-00921-6
Kim, Won Seog; Kim, Tae Min; Cho, Seok-Goo; Jarque, Isidro; Iskierka-Jażdżewska, Elżbieta; Poon, Li Mei; Prince, H Miles; Zhang, Huilai; Cao, Junning; Zhang, Mingzhi; Tessoulin, Benoît; Oh, Sung Yong; Lim, Francesca; Carpio, Cecilia; Tan, Tran-Der; Ayyappan, Sabarish; Gutierrez, Antonio; Cai, Jingxian; Ufkin, Melanie; Shariff, Saleem; Brouwer-Visser, Jurriaan; Chaudhry, Aafia; Mohamed, Hesham; Ambati, Srikanth; Walewski, Jan
B细胞
细胞生物学
淋巴瘤
免疫/内分泌
发表日期：2025
文献求助 收藏